PRNewsWire
16 Sept 2026, 13:48 UTC · 1h ago
Verdict
Headline leans bearish. We score CAPR −1.00 across four claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
4 claims · scored −1 bearish … +1 bullish · 1 new · 3 priced in
The FDA released briefing documents on July 27, 2026, stating that the benefit-risk assessment for deramiocel appears unfavorable due to a lack of evidence of effectiveness.
Priced inoccurred July 27, 2026
So whatThe resulting 64% price drop to $7.00 fundamentally reset the company's valuation based on the primary asset's viability.
More negative than 99% of claims this week
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
An AdCom panel voted 9-3 on July 29, 2026, concluding that available evidence does not support the efficacy of deramiocel for treating DMD-associated cardiomyopathy.
Priced inoccurred July 29, 2026
So whatThis non-binding vote contributed to a further 36% decline, bringing the share price down to $4.19.
More negative than 98% of claims this week
A securities class action lawsuit alleges Capricor made misleading statements by changing the statistical analysis plan for Deramiocel without FDA agreement prior to BLA resubmission.
Priced inlawsuit filed prior to Sept 16
More negative than 80% of claims this week
The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Capricor is September 28, 2026.
Newpress release dated Sep 16
So whatThe 12-day window until the deadline determines who will direct the litigation and potential recovery strategy.
More negative than 62% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a securities class action lawsuit following a massive stock price collapse and negative FDA feedback regarding the efficacy of its lead drug candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
10h ago
+1.2%
Price is moving against the score
$8.66 vs $8.56 close before publication (Sep 15) · not market-adjusted
CAPR chart →
